β-Carboline and chloroquine hybrids as potent antiplasmodial agents: Design, synthesis and biological evaluation.

IF 1.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Acta Pharmaceutica Pub Date : 2026-06-30 Print Date: 2026-06-01 DOI:10.2478/acph-2026-0016
Ana Penava, Lais Pessanha De Carvalho, Jana Held, Goran Poje, Zrinka Rajić, Ivana Perković
{"title":"<i>β</i>-Carboline and chloroquine hybrids as potent antiplasmodial agents: Design, synthesis and biological evaluation.","authors":"Ana Penava, Lais Pessanha De Carvalho, Jana Held, Goran Poje, Zrinka Rajić, Ivana Perković","doi":"10.2478/acph-2026-0016","DOIUrl":null,"url":null,"abstract":"<p><p>A series of thirteen novel <i>β</i>-carboline and chloroquine (CQ) hybrids was designed and synthesized. The compounds were evaluated for <i>in vitro</i> antiplasmodial activity against <i>Plasmodium falciparum</i> strains 3D7 (CQ-sensitive) and Dd2 (multidrug-resistant). All compounds exhibited potent activity, with <i>IC</i> <sub>50</sub> values in the nanomolar to low micromolar range, while retaining potency against the resistant strain (1.0 to 365.5 nmol L<sup>-1</sup> for 3D7 and from 2.2 to 2415.3 nmol L<sup>-1</sup> for Dd2 strain). Several compounds were more active against Dd2, then against 3D7 strain with resistance index (RI) lower than 1. Moreover, nearly all compounds showed lower RI values compared to CQ which additionally underscores their outstanding activity. At the highest tested concentration (250 μmol L<sup>-1</sup>), no cytotoxicity was observed in HepG2 cells, resulting in favourable selectivity indices expressed as lower limits. Overall, the obtained results confirm strong antiplasmodial activity of the <i>β</i>-carboline and chloroquine hybrids as promising antiplasmodial candidates, particularly due to their activity against resistant strains and improved selectivity.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"76 2","pages":"1-26"},"PeriodicalIF":1.8000,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2026-0016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

A series of thirteen novel β-carboline and chloroquine (CQ) hybrids was designed and synthesized. The compounds were evaluated for in vitro antiplasmodial activity against Plasmodium falciparum strains 3D7 (CQ-sensitive) and Dd2 (multidrug-resistant). All compounds exhibited potent activity, with IC 50 values in the nanomolar to low micromolar range, while retaining potency against the resistant strain (1.0 to 365.5 nmol L-1 for 3D7 and from 2.2 to 2415.3 nmol L-1 for Dd2 strain). Several compounds were more active against Dd2, then against 3D7 strain with resistance index (RI) lower than 1. Moreover, nearly all compounds showed lower RI values compared to CQ which additionally underscores their outstanding activity. At the highest tested concentration (250 μmol L-1), no cytotoxicity was observed in HepG2 cells, resulting in favourable selectivity indices expressed as lower limits. Overall, the obtained results confirm strong antiplasmodial activity of the β-carboline and chloroquine hybrids as promising antiplasmodial candidates, particularly due to their activity against resistant strains and improved selectivity.

β-卡波林和氯喹的杂合物作为有效的抗疟原虫药物:设计、合成和生物学评价。
设计并合成了13个新型β-碳碱和氯喹(CQ)杂种化合物。评价化合物对恶性疟原虫3D7 (cq敏感)和Dd2(多重耐药)的体外抗疟原虫活性。所有化合物均表现出有效的活性,ic50值在纳摩尔到低微摩尔范围内,同时对抗性菌株保持效力(3D7为1.0 ~ 365.5 nmol -1, Dd2为2.2 ~ 2415.3 nmol -1)。部分化合物对Dd2活性较强,对3D7活性次之,抗性指数(RI)小于1。此外,与CQ相比,几乎所有化合物的RI值都较低,这进一步表明它们具有出色的活性。在最高浓度(250 μmol L-1)下,对HepG2细胞无细胞毒性作用,具有较好的选择性指标。总的来说,这些结果证实了β-碳碱和氯喹杂交体具有很强的抗疟原虫活性,特别是由于它们对耐药菌株的活性和更高的选择性,它们是有希望的抗疟原虫候选物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmaceutica
Acta Pharmaceutica PHARMACOLOGY & PHARMACY-
CiteScore
5.20
自引率
3.60%
发文量
20
审稿时长
>12 weeks
期刊介绍: AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书